Accellacare UK Limited - Limited company accounts 22.3
Accellacare UK Limited - Limited company accounts 22.3
REGISTERED NUMBER: |
STRATEGIC REPORT, |
REPORT OF THE DIRECTORS AND |
FINANCIAL STATEMENTS |
FOR THE YEAR ENDED 31 DECEMBER 2021 |
FOR |
ACCELLACARE UK LIMITED |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
CONTENTS OF THE FINANCIAL STATEMENTS |
for the year ended 31 December 2021 |
Page |
Company Information | 1 |
Strategic Report | 2 |
Report of the Directors | 4 |
Report of the Independent Auditors | 6 |
Income Statement | 10 |
Other Comprehensive Income | 11 |
Balance Sheet | 12 |
Statement of Changes in Equity | 13 |
Notes to the Financial Statements | 14 |
ACCELLACARE UK LIMITED |
COMPANY INFORMATION |
for the year ended 31 December 2021 |
DIRECTORS: |
SECRETARY: |
REGISTERED OFFICE: |
REGISTERED NUMBER: |
AUDITORS: |
Chartered Accountants |
Statutory Auditors |
1110 Elliott Court |
Herald Avenue |
Coventry Business Park |
Coventry |
West Midlands |
CV5 6UB |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
STRATEGIC REPORT |
for the year ended 31 December 2021 |
The directors present their strategic report for the year ended 31 December 2021. |
PRINCIPAL ACTIVITIES |
The principal activity of Accellacare UK Limited ("the Company") is to provide clinical research services to the pharmaceutical industry. This is primarily done through carrying out clinical trials at our research sites globally. There has been a drop in activity compared with the prior reporting period which is mainly attributable to one large study having reduced activity as it neared completion. |
REVIEW OF BUSINESS |
The results of the Company are set out on page 10 of the financial statements. |
The directors do not envisage a significant change in the activities of the Company over the coming year. |
PRINCIPAL RISKS AND UNCERTAINTIES |
The company is exposed to financial and business risks as noted below. The company has in place risk management policies that seek to limit the adverse effect of these risks on the financial performance of the company. |
Credit risk |
The company's credit risk is primarily attributable to its trade debtors and unbilled receivables. The amounts presented in the Statement of Financial Position is net of allowances for doubtful debts, estimated by management based on prior experience, the current economic environment or specific customer issues. The company has implemented polices that require appropriate assessments of potential customers and reviews of existing customer histories before a sale is made. |
Foreign exchange risk |
The company operates internationally and as such not all contracts will be in the company's functional currency. Contracts usually span a few years and are forecasted to return a certain level of profit. Fluctuations in currency exchange rates may have an impact on the forecasted profit. Management consider this to be an acceptable level of risk. |
Business risk |
There are risks and uncertainties relevant to the company's business, financial condition and the results of operations which may affect future performance. The factors listed below are amongst those which could cause its actual results to differ materially from expected or historical results. |
Continuation of work undertaken |
Clinical trials are complex and the data collected is regularly monitored for both safety and efficacy reasons. If issues arise on a trial, it can be terminated early causing a reduction in future revenue from that trial. Management mitigates this risk by participating in multiple studies for different clients. |
Regulatory authorities |
Our work is subject to inspections from regulatory authorities and we need to ensure that our processes and work meets the expected standards. Management mitigate this risk by maintaining strong oversight through regular quality control and quality assurance reviews. |
Recruitment of qualified employees |
The success of the company's business depends on its ability to attract and retain qualified clinical, professional and administrative staff. The company believes that its reputation, growth prospects, good compensation and benefits packages, together with the excellent training schemes offered, allows it to offer broad experience to existing and prospective employees. |
Reliance on information technology |
The company is reliant on information technology systems. Any disruption to these systems due to internal or external factors could materially affect the company's operations. Management utilise a number of information technology security measures to mitigate this risk. |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
STRATEGIC REPORT |
for the year ended 31 December 2021 |
KEY PERFORMANCE INDICATORS |
12 months to December 2021 |
9 months to December 2020 |
Movement |
£ | £ | % |
Turnover | 9,404 | 8,703 | 8.05 |
Operating profit | 981 | 1,070 | (8.32 | ) |
Trade debtors | 2,311 | 2,971 | (22.21 | ) |
Accrued income and retentions | 2,498 | 3,698 | (32.45 | ) |
Cash at bank | 823 | 3,018 | (72.73 | ) |
Average number of employees | 115 | 150 | (23.33 | ) |
ON BEHALF OF THE BOARD: |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
REPORT OF THE DIRECTORS |
for the year ended 31 December 2021 |
The directors present their report with the financial statements of the company for the year ended 31 December 2021. |
PRINCIPAL ACTIVITY |
The principal activity of the company in the year under review was that of clinical research. |
DIVIDENDS |
No dividends will be distributed for the year ended 31 December 2021. |
DIRECTORS |
The directors shown below have held office during the whole of the period from 1 January 2021 to the date of this report. |
POST BALANCE SHEET EVENTS |
There have been no events subsequent to the year end requiring adjustment to, or disclosure in, the financial statements. |
COMPANY INFORMATION |
Icon PLC (incorporated in Ireland) is regarded by the directors as being the company's ultimate parent company. |
Accellacare UK Limited is wholly owned by VSK (Kenilworth) Limited.I CON Clinical Research (U.K.) Limited acquired 60.22% of VSK (Kenilworth) Limited on the 23 May 2019. There was a put and call option arrangement in place for ICON Clinical Research (U.K.) Limited to acquire the remaining 39.28%. On 9th March 2020 the ICON Clinical Research (U.K.) Limited exercised its option to call the remaining 39.78% of the issued share capital of VSK (Kenilworth) Limited. On the 17th July 2020, ICON Clinical Research (U.K.) Limited acquired the remaining 39.78% of the issued share capital of VSK (Kenilworth) Limited and became the sole shareholder. |
Please refer to the consolidated financial statements of ICON plc which are available from the Companies Registration Office, Bloom House, Gloucester Place Lower, Dublin 1, Ireland for additional risks and uncertainties facing the Group that may have adversely affect the business. |
There have been no other significant events since the balance sheet date requiring disclosure in the financial statements |
STATEMENT OF DIRECTORS' RESPONSIBILITIES |
The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations. |
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to: |
- | select suitable accounting policies and then apply them consistently; |
- | make judgements and accounting estimates that are reasonable and prudent; |
- | prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business. |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
REPORT OF THE DIRECTORS |
for the year ended 31 December 2021 |
STATEMENT OF DIRECTORS' RESPONSIBILITIES - continued |
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. |
STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS |
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information. |
AUDITORS |
The auditors, Luckmans Duckett Parker Limited, will be proposed for re-appointment at the forthcoming Annual General Meeting. |
ON BEHALF OF THE BOARD: |
REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF |
ACCELLACARE UK LIMITED |
Opinion |
We have audited the financial statements of Accellacare UK Limited (the 'company') for the year ended 31 December 2021 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 101 'Reduced Disclosure Framework' (United Kingdom Generally Accepted Accounting Practice). |
In our opinion the financial statements: |
- | give a true and fair view of the state of the company's affairs as at 31 December 2021 and of its profit for the year then ended; |
- | have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and |
- | have been prepared in accordance with the requirements of the Companies Act 2006. |
Basis for opinion |
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. |
Conclusions relating to going concern |
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. |
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. |
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. |
Other information |
The directors are responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon. |
Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. |
In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. |
Opinions on other matters prescribed by the Companies Act 2006 |
In our opinion, based on the work undertaken in the course of the audit: |
- | the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and |
- | the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements. |
REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF |
ACCELLACARE UK LIMITED |
Matters on which we are required to report by exception |
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors. |
We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion: |
- | adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or |
- | the financial statements are not in agreement with the accounting records and returns; or |
- | certain disclosures of directors' remuneration specified by law are not made; or |
- | we have not received all the information and explanations we require for our audit. |
Responsibilities of directors |
As explained more fully in the Statement of Directors' Responsibilities set out on pages four and five, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. |
In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so. |
REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF |
ACCELLACARE UK LIMITED |
Auditors' responsibilities for the audit of the financial statements |
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. |
The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below: |
In identifying and assessing the risk of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following: |
- reference to past history and experience of the Entity, |
- enquiry of management, including obtaining and reviewing supporting documentation concerning |
the Entity's procedures relating to: |
- identifying and complying with laws and regulations and whether they were aware of any instances |
of non-compliance; |
- detection and response to risk of fraud and whether they were aware of any actual or suspected |
instances of fraud. |
- assessment of the controls and processes that the Entity has in place to mitigate risk |
Our assessments included the identification of the following potential areas for fraud: |
- Management override of control; |
- Revenue recognition, particularly in respect of delivery of services |
We design audit procedures by tailored and directed testing to aid and support the determined level of risk. In response to the assessed risk we plan audit tests and procedures that target specific areas where misstatement may occur. These procedures and the extent to which they are capable of detecting |
irregularities, including fraud, are detailed below: |
- We critically assessed the appropriateness and tested the application of the revenue and cost |
recognition policies |
- We tested the appropriateness of accounting journals and other adjustments made in the |
preparation of the financial statements |
- We reviewed the Entity's accounting policies for non-compliance with relevant standards. |
- We made enquiries of management and reviewed correspondence with the relevant authorities to |
identify any irregularities or instances of non-compliance with laws and regulations |
In performing an audit in accordance with UK GAAP, we exercise professional judgement and maintain |
professional scepticism throughout the audit process. |
The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from |
error, as fraud may involve collusion or override of internal controls. There are inherent limitations in the audit procedures performed. |
A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors. |
REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF |
ACCELLACARE UK LIMITED |
Use of our report |
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed. |
for and on behalf of |
Chartered Accountants |
Statutory Auditors |
1110 Elliott Court |
Herald Avenue |
Coventry Business Park |
Coventry |
West Midlands |
CV5 6UB |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
INCOME STATEMENT |
for the year ended 31 December 2021 |
Year Ended | Period |
31.12.21 | 1.4.20 to 31.12.20 |
Notes | £ | £ | £ | £ |
TURNOVER | 3 |
Other operating income |
9,786,785 | 8,764,986 |
Cost of sales |
8,232,524 | 6,438,972 |
Staff costs | 4 |
Depreciation |
Lease expense |
Other operating expenses |
7,252,005 | 5,368,499 |
OPERATING PROFIT |
Interest receivable and similar income |
983,669 | 1,074,734 |
Amounts written off investments | 5 | - | 100,051 |
983,669 | 974,683 |
Interest payable and similar expenses | 6 |
PROFIT BEFORE TAXATION | 7 |
Tax on profit | 8 |
PROFIT FOR THE FINANCIAL YEAR |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
OTHER COMPREHENSIVE INCOME |
for the year ended 31 December 2021 |
Period |
1.4.20 |
Year Ended | to |
31.12.21 | 31.12.20 |
Notes | £ | £ |
PROFIT FOR THE YEAR |
OTHER COMPREHENSIVE INCOME | - | - |
TOTAL COMPREHENSIVE INCOME FOR THE YEAR |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
BALANCE SHEET |
31 December 2021 |
2021 | 2020 |
Notes | £ | £ | £ | £ |
FIXED ASSETS |
Tangible assets | 9 |
Investments | 10 |
CURRENT ASSETS |
Debtors | 11 |
Cash at bank |
CREDITORS |
Amounts falling due within one year | 12 |
NET CURRENT ASSETS |
TOTAL ASSETS LESS CURRENT LIABILITIES |
CREDITORS |
Amounts falling due after more than one year |
13 |
( |
) |
( |
) |
PROVISIONS FOR LIABILITIES | 16 | ( |
) | ( |
) |
ACCRUALS AND DEFERRED INCOME | 17 | ( |
) | ( |
) |
NET ASSETS |
CAPITAL AND RESERVES |
Called up share capital | 18 |
Capital redemption reserve | 19 |
Retained earnings | 19 |
SHAREHOLDERS' FUNDS |
The financial statements were approved by the Board of Directors and authorised for issue on |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
STATEMENT OF CHANGES IN EQUITY |
for the year ended 31 December 2021 |
Called up | Capital |
share | Retained | redemption | Total |
capital | earnings | reserve | equity |
£ | £ | £ | £ |
Balance at 1 April 2020 |
Changes in equity |
Total comprehensive income | - |
Balance at 31 December 2020 | 5,593,435 |
Changes in equity |
Total comprehensive income | - | - |
Balance at 31 December 2021 |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
NOTES TO THE FINANCIAL STATEMENTS |
for the year ended 31 December 2021 |
1. | STATUTORY INFORMATION |
Accellacare UK Limited is a private company, limited by shares, registered in England and Wales. The Company's registered office is 500 South Oak Way, Green Park, Reading, England, RG2 6AD, United Kingdom. The company registered number is 04105540. |
2. | ACCOUNTING POLICIES |
Basis of preparation |
The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 101 "Reduced Disclosure Framework": |
• | the requirements of paragraph 33(c) of IFRS 5 Non Current Assets Held for Sale and Discontinued Operations; |
• | the requirements of IFRS 7 Financial Instruments: Disclosures; |
• | the requirements of paragraphs 91 to 99 of IFRS 13 Fair Value Measurement; |
• | the requirements of paragraph 52 of IFRS 16 Leases; |
the requirements of paragraph 58 of IFRS 16; |
• | the requirements of the second sentence of paragraph 110 and paragraphs 113(a), 114, 115, 118, 119(a) to (c), 120 to 127 and 129 of IFRS 15 Revenue from Contracts with Customers; |
• | the requirement in paragraph 38 of IAS 1 Presentation of Financial Statements to present comparative information in respect of: |
- | paragraph 79(a)(iv) of IAS 1; and |
- | paragraph 73(e) of IAS 16 Property, Plant and Equipment; |
• | the requirements of paragraphs 10(d), 10)(f), 16, 38A, 38B, 38C, 38D, 40A, 40B, 40C, 40D and 111 of IAS 1 Presentation of Financial Statements; |
• | the requirements of paragraphs 134 to 136 of IAS 1 Presentation of Financial Statements; |
• | the requirements of IAS 7 Statement of Cash Flows; |
• | the requirements of paragraphs 30 and 31 of IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors; |
• | the requirements of paragraphs 17 and 18A of IAS 24 Related Party Disclosures; |
• | the requirements in IAS 24 Related Party Disclosures to disclose related party transactions entered into between two or more members of a group; |
• | the requirements of paragraphs 134(d) to 134(f) and 135(c) to 135(e) of IAS 36 Impairments of Assets. |
Tangible fixed assets |
Improvements to property | - |
Fixtures and fittings | - |
Financial instruments |
The company has elected to apply the provisions of IFRS 7 "Financial Instruments: Disclosures", as permitted by FRS 101, to all of its financial instruments. |
Financial instruments are recognised when the company becomes party to the contractual provisions of the instrument. |
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and liability and settle simultaneously. |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
for the year ended 31 December 2021 |
2. | ACCOUNTING POLICIES - continued |
Taxation |
Current taxes are based on the results shown in the financial statements and are calculated according to local tax rules, using tax rates enacted or substantially enacted by the balance sheet date. |
Research and development |
Expenditure on research and development is written off in the year in which it is incurred. |
Foreign currencies |
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result. |
Leases |
Leases are recognised as operating leases. The lease liability is initially recognised at the present value of the lease payments which have not yet been made and subsequently measured under the amortised cost method. The initial cost of the right-of-use asset comprises the amount of the initial measurement of the lease liability, lease payments made prior to the lease commencement date, initial direct costs and the estimated costs of removing or dismantling the underlying asset per the conditions of the contract. |
Where ownership of the right-of-use asset transfers to the lessee at the end of the lease term, the right-of-use asset is depreciated over the asset’s remaining useful life. If ownership of the right-of-use asset does not transfer to the lessee at the end of the lease term, depreciation is charged over the shorter of the useful life of the right-of-use asset and the lease term. |
Employee benefit costs |
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to the income statement in the period to which they relate. |
Government grants |
Government grants are recognised as other operating income where receivable. |
3. | TURNOVER |
The turnover and profit before taxation are attributable to the one principal activity of the company. |
An analysis of turnover by class of business is given below: |
Period |
1.4.20 |
Year Ended | to |
31.12.21 | 31.12.20 |
£ | £ |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
for the year ended 31 December 2021 |
3. | TURNOVER - continued |
An analysis of turnover by geographical market is given below: |
Period |
1.4.20 |
Year Ended | to |
31.12.21 | 31.12.20 |
£ | £ |
United Kingdom and EMEA |
United States of America |
4. | EMPLOYEES AND DIRECTORS |
Period |
1.4.20 |
Year Ended | to |
31.12.21 | 31.12.20 |
£ | £ |
Wages and salaries | 4,893,767 | 3,982,209 |
Social security costs |
Other pension costs |
The average number of employees during the year was as follows: |
Period |
1.4.20 |
Year Ended | to |
31.12.21 | 31.12.20 |
Clinical | 107 | 121 |
Non-Clinical | 8 | 29 |
Period |
1.4.20 |
Year Ended | to |
31.12.21 | 31.12.20 |
£ | £ |
Directors' remuneration |
Directors' pension contributions to money purchase schemes |
5. | AMOUNTS WRITTEN OFF INVESTMENTS |
Period |
1.4.20 |
Year Ended | to |
31.12.21 | 31.12.20 |
£ | £ |
Investment provision | - | 100,051 |
The provision for 2020 was made to impair the carrying value of the investment in Medinova Lakeside Clinical Research Ltd. |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
for the year ended 31 December 2021 |
6. | INTEREST PAYABLE AND SIMILAR EXPENSES |
Period |
1.4.20 |
Year Ended | to |
31.12.21 | 31.12.20 |
£ | £ |
Bank interest |
Interest expense on leasing arrangements |
7. | PROFIT BEFORE TAXATION |
The profit before taxation is stated after charging/(crediting): |
Period |
1.4.20 |
Year Ended | to |
31.12.21 | 31.12.20 |
£ | £ |
Leases | 67,259 | - |
Depreciation - owned assets |
Profit on disposal of fixed assets | ( |
) |
Auditors' remuneration |
Foreign exchange differences | ( |
) |
8. | TAXATION |
Analysis of tax expense |
Period |
1.4.20 |
Year Ended | to |
31.12.21 | 31.12.20 |
£ | £ |
Current tax: |
Tax | 128,255 | 209,324 |
Prior year adjustment | 84,031 | (1,950 | ) |
Total current tax | 212,286 | 207,374 |
Deferred tax: |
Deferred tax | ( |
) |
Prior year adjustment for |
deferred taxation | - | 40,948 |
Effects of changes in tax rate | 29,274 | - |
Total deferred tax | ( |
) |
Total tax expense in income statement |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
for the year ended 31 December 2021 |
8. | TAXATION - continued |
Factors affecting the tax expense |
The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below: |
Period |
1.4.20 |
Year Ended | to |
31.12.21 | 31.12.20 |
£ | £ |
Profit before income tax |
Profit multiplied by the standard rate of corporation tax in the UK of |
179,686 |
182,761 |
Effects of: |
Capital allowances for the period in excess of depreciation | (6,138 | ) | 47,282 |
Non-deductible expenses | - | 29,770 |
Prior year amendment | - | (1,950 | ) |
Group losses relief | (49 | ) | (6,896 | ) |
Impact of changes in tax rates | 29,274 | - |
Tax expense |
9. | TANGIBLE FIXED ASSETS |
Improvements | Fixtures |
Short | to | and | Computer |
leasehold | property | fittings | equipment | Totals |
£ | £ | £ | £ | £ |
COST |
At 1 January 2021 |
Additions |
At 31 December 2021 |
DEPRECIATION |
At 1 January 2021 |
Charge for year |
At 31 December 2021 |
NET BOOK VALUE |
At 31 December 2021 |
At 31 December 2020 |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
for the year ended 31 December 2021 |
10. | INVESTMENTS |
Shares in |
group |
undertakings |
£ |
COST |
At 1 January 2021 |
and 31 December 2021 | 2,656 |
NET BOOK VALUE |
At 31 December 2021 | 2,656 |
At 31 December 2020 | 2,656 |
The company's investments at the Balance Sheet date in the share capital of companies include the following: |
Registered office: Calle del Marqués de la Valdavia, 103, 28100 Alcobendas, Madrid, Spain |
Nature of business: |
% |
Class of shares: | holding |
This company was formerly known as Medinova Investigacion y Desarollo SL |
Accellacare South Africa (PTY) LTD (formerly Medinova Merc Clinical Research PTY SA Limited) |
Registered office:Block 29 Second Floor, The Highlands Estate, The Woodlands, Woodlands Drive, Woodmead, Gauteng, 2191, South Africa (formerly 11 Dolerite Crescent, Aerorand, Middelburg, Mpumalanga 1050, South Africa) |
Nature of business: Clinical Research |
% |
Class of shares: | holding |
Ordinary | 51% |
Registered office: 500 South Oak Way, Green Park, Reading, England, RG2 6AD, United Kingdom |
Nature of business: |
% |
Class of shares: | holding |
Registered office: 500 South Oak Way, Green Park, Reading, England, RG2 6AD, United Kingdom |
Nature of business: |
% |
Class of shares: | holding |
Registered office: 500 South Oak Way, Green Park, Reading, England, RG2 6AD, United Kingdom |
Nature of business: |
% |
Class of shares: | holding |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
for the year ended 31 December 2021 |
11. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
2021 | 2020 |
£ | £ |
Trade debtors |
Amounts owed by group undertakings |
Other debtors |
Tax | 536,865 | 948,287 |
VAT |
Prepayments |
Accrued income and retentions | 2,497,869 | 3,697,957 |
12. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
2021 | 2020 |
£ | £ |
Leases (see note 14) |
Trade creditors |
Amounts owed to group undertakings |
Social security and other taxes |
Other creditors |
Accrued expenses |
. |
. |
. |
13. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |
2021 | 2020 |
£ | £ |
Leases (see note 14) |
. |
. |
. |
14. | FINANCIAL LIABILITIES - BORROWINGS |
2021 | 2020 |
£ | £ |
Current: |
Leases (see note 15) | 334,249 | 230,895 |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
for the year ended 31 December 2021 |
14. | FINANCIAL LIABILITIES - BORROWINGS - continued |
2021 | 2020 |
£ | £ |
Non-current: |
Leases (see note 15) | 873,283 | 573,628 |
Terms and debt repayment schedule |
1 year or | More than |
less | 1-2 years | 2-5 years | 5 years | Totals |
£ | £ | £ | £ | £ |
Leases | 334,249 | 281,749 | 531,029 | 60,505 | 1,207,532 |
15. | LEASING |
Other leases |
Period |
1.4.20 |
Year Ended | to |
31.12.21 | 31.12.20 |
£ | £ |
Short-term leases | 67,259 | - |
Lease liabilities |
Minimum lease payments fall due as follows: |
2021 | 2020 |
£ | £ |
Gross obligations repayable: |
Within one year | 354,417 | 245,553 |
Between one and five years | 841,066 | 524,975 |
In more than five years | 61,684 | 78,414 |
1,257,167 | 848,942 |
Finance charges repayable: |
Within one year | 20,168 | 14,658 |
Between one and five years | 28,288 | 26,608 |
In more than five years | 1,179 | 3,153 |
49,635 | 44,419 |
Net obligations repayable: |
Within one year | 334,249 | 230,895 |
Between one and five years | 812,778 | 498,367 |
In more than five years | 60,505 | 75,261 |
1,207,532 | 804,523 |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
for the year ended 31 December 2021 |
16. | PROVISIONS FOR LIABILITIES |
2021 | 2020 |
£ | £ |
Deferred tax |
Accelerated capital allowances | 121,972 | 73,747 |
Deferred tax | ( |
) |
107,837 | 117,340 |
Deferred |
tax |
£ |
Balance at 1 January 2021 |
Credit to Income Statement during year | (9,503 | ) |
Balance at 31 December 2021 |
Following Finance Act 2021, the corporation tax rate will increase from 19% to 25% with effect from 1 April 2023 and this will have a consequential effect on the company's future tax charge. |
The increase in the UK corporation tax rate to 25% (effective 1 April 2023) was substantially enacted on 24 May 2021. Therefore, the deferred tax position at 31 December 2021 has been calculated at 25%. |
17. | ACCRUALS AND DEFERRED INCOME |
2021 | 2020 |
£ | £ |
Accruals and deferred income | 3,398,664 | 6,390,675 |
31/12/2021 | 31/12/2020 |
£ | £ |
Deferred Income brought forward | 6,390,675 | 5,564,097 |
Released during the year | (2,992,011 | ) | - |
Deferred during the year | - | 826,578 |
Deferred Income carried forward | 3,398,664 | 6,390,675 |
18. | CALLED UP SHARE CAPITAL |
Allotted, issued and fully paid: |
Number: | Class: | Nominal value: | 31/12/2020 | 31/03/2020 |
£ | £ |
910 | Ordinary | £1 | 910 | 910 |
ACCELLACARE UK LIMITED (REGISTERED NUMBER: 04105540) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
for the year ended 31 December 2021 |
19. | RESERVES |
Capital |
Retained | redemption |
earnings | reserve | Totals |
£ | £ | £ |
At 1 January 2021 | 5,593,525 |
Profit for the year |
At 31 December 2021 | 6,336,468 |
20. | ULTIMATE PARENT COMPANY |
Icon PLC (incorporated in Ireland ) is regarded by the directors as being the company's ultimate parent company. |
Accellacare UK Limited is wholly owned by VSK (Kenilworth) Limited. ICON Clinical Research (U.K.) Limited acquired 60.22% of VSK (Kenilworth) Limited on the 23 May 2019. There was a put and call option arrangement in place for ICON Clinical Research (U.K.) Limited to acquire the remaining 39.28%. On 9th March 2020 the ICON Clinical Research (U.K.) Limited exercised its option to call the remaining 39.78% of the issued share capital of VSK (Kenilworth) Limited. On the 17th July 2020, ICON Clinical Research (U.K.) Limited acquired the remaining 39.78% of the issued share capital of VSK (Kenilworth) Limited and became the sole shareholder. |